The potential for the use of insulin lispro in pregnancy complicated by diabetes

Carr, Kate; Lindow, Stephen W.; Masson, E. A.

doi:10.1080/14767050600746514

Cited by 3 publications

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of this, they have pharmacokinetic properties that allow concentrations to be reached approximately twice as fast as RI [2,7,8], meaning a quicker onset of action compared to RI (15 vs. 30 min). They also have shorter time to peak action (30-70 min vs. 1-3 h) and a shorter duration of action (2-5 vs. 7-8 h), providing advantages in rapid postprandial glycemic control, which is more convenient for the patient [2,9,10]. …”

Section: Introductionmentioning

confidence: 99%

Pregnancy and Neonatal Outcomes in Gestational Diabetes Treated with Regular Insulin or Fast-Acting Insulin Analogues

You

Choi

Roh

et al. 2015

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background/Aims: Fast-acting insulin analogues (FAIAs) are being used more frequently during pregnancy. Previous studies comparing regular insulin (RI) and FAIA consist primarily of women enrolled with pre-existing diabetes; therefore, we compared pregnancy and neonatal outcomes in women with gestational diabetes. Methods: We retrospectively investigated 197 pregnant women with gestational diabetes mellitus (GDM) requiring insulin treatment for glycemic control. Individuals were divided into 2 groups: RI (n = 55) and FAIA (aspart or lispro; n = 142). Pregnancy outcomes, including caesarean section rate, and neonatal outcomes, including macrosomia and ponderal index, were compared between groups. Results: There were no significant differences in maternal baseline characteristics (age, parity, body mass index and weight gain) between groups or in haemoglobinA_1c before delivery. The frequency of emergency caesarean section (caesarean section after trial of labor) was not significantly different between groups (RI 16.7%, FAIA 24.7%; p = 0.452). There were no differences in frequencies of macrosomia (RI 3.4%, FAIA 6.5%; p = 0.518), ponderal index (RI 2.65 ± 0.5, FAIA 2.71 ± 0.5; p = 0.322), cranial-thoracic circumference ratio (RI 1.07 ± 0.06, FAIA 1.07 ± 0.06; p = 0.386) or neonatal hypoglycemia (RI 5.1%, FAIA 5.8%; p = 1.000). Conclusion: Our data indicate that FAIA achieves similar pregnancy and neonatal outcomes in GDM compared with RI. Considering patient convenience, FAIA may be better to use during pregnancy.

show abstract

Section: Introductionmentioning

confidence: 99%

Pregnancy and Neonatal Outcomes in Gestational Diabetes Treated with Regular Insulin or Fast-Acting Insulin Analogues

You

Choi

Roh

et al. 2015

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

Is insulin lispro safe in pregnant women: Does it cause any adverse outcomes on infants or mothers?

Aydın

Berker

Direktör

et al. 2008

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

Insulin Lispro

Simpson

McCormack

Keating

et al. 2007

Drugs

View full text Add to dashboard Cite

Insulin lispro, alone (Humalog) or as premixture (Humalog Mix25 or Humalog Mix50) is indicated for the treatment of hyperglycaemia in diabetes mellitus in many countries worldwide. It is a recombinant human insulin analogue and, except for the transposition of two amino acids, is identical to endogenous human insulin. Insulin lispro has a faster onset of action and shorter duration of activity than regular human insulin, and the time-action profile of insulin lispro mimics that of the physiological response of endogenous human insulin to food intake. In diabetic patients, from young children to the elderly, it has demonstrated postprandial blood glucose control similar to or better than that achieved with regular human insulin, without an increased risk of hypoglycaemia. In some trials, the risk of hypoglycaemia, including nocturnal episodes, was less in insulin lispro recipients than in regular human insulin recipients. Insulin lispro alone, or as a premixture with the longer-acting insulin neutral protamine lispro, can be administered immediately before or after meals. This convenient and flexible injection schedule may enable patients, including those with a non-routine lifestyle or unpredictable eating or exercising habits, to achieve the tight glycaemic control required to minimise long-term complications of diabetes and contributes to patient satisfaction with treatment.

show abstract

The potential for the use of insulin lispro in pregnancy complicated by diabetes

Cited by 3 publications

References 43 publications

Pregnancy and Neonatal Outcomes in Gestational Diabetes Treated with Regular Insulin or Fast-Acting Insulin Analogues

Pregnancy and Neonatal Outcomes in Gestational Diabetes Treated with Regular Insulin or Fast-Acting Insulin Analogues

Is insulin lispro safe in pregnant women: Does it cause any adverse outcomes on infants or mothers?

Insulin Lispro

Contact Info

Product

Resources

About